Korean listed pharmaceutical companies with December fiscal year are releasing sluggish reports.
Korean listed firms require to release disclosure information if a company’s sales revenue, operating income (or less), and net income (or less) have changed by over 30% companied to the previous year, and most of them were subject to announce due to poor performance.
Companies that made related disclosures until the 8th and after the 9th also announced disappointing results.
In particular, Kukje Pharma, Shin Poong Pharmaceutical, and Yungjin Pharm. Saw their operating income turn into a deficit while their sales fell from the previous year (2020). Dongsung Pharmaceutical also suffer a bigger loss as sales declined.
HK Inno.N, whose sales increased by nearly 30%, saw its operating income fall by more than 40%, and Samil Pharmaceutical was also subject to disclosure as its operating income plunged more than 90% despite its sales growth of nearly 10%.
Chong Kun Dang Pharmaceutical’s sales rose slightly, but its operating income fell more than 30%, and Daewon Pharmaceutical’s sales gained by nearly 15%, but its operating income decreased by about 20%.
On the other hand, JW Pharmaceutical announced its preliminary financial report with a good performance by succeeding in turning into a large surplus with double-digit growth in sales.
Withus Pharmaceutical recorded a three-digit increase in both sales and operating income, and Hana Pharm also saw its sales and operating income increase by more than 10%.
The three companies, CMG Pharmaceutical, Daihan Pharmaceutical, and Handok noted a slight decrease in operating income despite an increase in sales, but a significant increase in net income.
Meanwhile, among the companies that disclosed until the 8th, Kyongbo Pharmaceutical, SamChunDang Pharm, Seoul Pharma, CKD Bio, and Hyundai Pharmaceutical turned into deficits, while Samjin Pharmaceutical and Korea Arlico Pharm saw their operating income drop sharply.
JW Shinyak succeeded in turning black, and the operating income of Jin Yang Pharmaceutical, Hanmi Pharmaceutical, and HanAll Biopharma soared.
